-
公开(公告)号:US5618831A
公开(公告)日:1997-04-08
申请号:US242834
申请日:1994-05-16
申请人: Tadao Shishido , Masayuki Kawakami , Akihiko Ikegawa , Toshinao Ukai , Keizo Koya , Lan B. Chen
发明人: Tadao Shishido , Masayuki Kawakami , Akihiko Ikegawa , Toshinao Ukai , Keizo Koya , Lan B. Chen
IPC分类号: A61K31/427 , A61K31/428 , A61K31/4439 , A61K31/4709 , A61K31/4725 , A61K31/506 , A61K31/425 , A61K31/44 , A61K31/47 , A61K31/505
CPC分类号: A61K31/541 , A61K31/427 , A61K31/428 , A61K31/4439 , A61K31/4709 , A61K31/4725 , A61K31/506
摘要: A pharmaceutical composition for treatment of cancer in an animal comprising:(A) a therapeutically effective amount of at least one compound selected from the group consisting of compounds represented by the General Formula (I). ##STR1## wherein Z.sub.1 and Z.sub.2, which may be the same or different, each represents an atomic group necessary to form a 5- or 6-membered ring;R.sub.1, R.sub.2 and R.sub.3, which may be the same or different, each represents an alkyl group or an aryl group;L.sub.1 and L.sub.2 each represents a methine group or a substituted methine group;X represents a pharmaceutically acceptable anion;k represents a number necessary for electrical charge balance;n represents 0 or 1; and(B) a pharmaceutically acceptable carrier or diluent.
摘要翻译: 一种用于治疗动物癌症的药物组合物,其包含:(A)治疗有效量的至少一种选自由通式(I)表示的化合物的化合物。 (I)其中Z1和Z2可以相同或不同,分别代表形成5-或6-元环所必需的原子团; R 1,R 2和R 3可以相同或不同,表示烷基或芳基; L1和L2各自表示次甲基或取代的次甲基; X表示药学上可接受的阴离子; k表示电荷平衡所需的数字; n表示0或1; 和(B)药学上可接受的载体或稀释剂。
-
公开(公告)号:US5360803A
公开(公告)日:1994-11-01
申请号:US972935
申请日:1992-11-06
申请人: Tadao Shishido , Lan B. Chen
发明人: Tadao Shishido , Lan B. Chen
IPC分类号: A61K31/41 , A61K31/415 , A61K31/42 , A61K31/425 , A61K31/426 , A61K31/428 , A61K31/44 , A61K31/4427 , A61K31/47 , A61K31/495 , A61K31/50 , A61K31/505 , A61K31/555 , A61P35/00 , C07D277/20 , C07D277/34 , C07D277/66 , C07D277/84 , C07D401/14 , C07D413/14 , C07D417/04 , C07D417/14 , C07D421/14 , C07D471/04 , C07D513/04
CPC分类号: A61K31/44 , A61K31/42 , A61K31/425 , A61K31/47 , A61K31/495 , A61K31/50 , A61K31/505 , A61K31/555
摘要: A pharmaceutical composition for treatment of cancer comprises:(A) a therapeutically effective amount of at least one compound selected from the group consisting of compounds represented by the General Formula (I) ##STR1## wherein X.sub.1 and X.sub.2, which may be the same or different, each represents O, S, Se, --CH.dbd.CH--, ##STR2## Y.sub.1 represents O, S, Se, or ##STR3## R.sub.1 and R.sub.3, which may be the same or different, each represents an alkyl group;R.sub.2 represents an alkyl group, an aryl group or a heterocyclic group;Z.sub.1 and Z.sub.2, which may be the same or different, each represents an atomic group necessary to form a 5- or 6-membered ring;L.sub.1 represents a methine group or L.sub.1 and R.sub.3 may combine and form a 5- or 6-membered ring;R.sub.4 and R.sub.5, which may be the same or different, each represents a alkyl group;R.sub.6 and R.sub.7, which may be the same or different, each represents an alkyl group or an aryl group;Q represents a pharmaceutically acceptable anion;l represents 1 or 2;m and n, which may be the same or different, each represents 0 or 1; and(B) a pharmaceutically acceptable carrier or diluent.
摘要翻译: 用于治疗癌症的药物组合物包括:(A)治疗有效量的至少一种选自由通式(I)表示的化合物的化合物,其中X1和X2可以是 相同或不同,各自表示O,S,Se,-CH = CH-,
Y1表示O,S,Se或者可以相同或不同的R 1和R 3各自表示烷基 组; R2表示烷基,芳基或杂环基; Z 1和Z 2可以相同或不同,表示形成5-或6-元环所必需的原子团; L1表示次甲基或L1和R3可以结合形成5-或6-元环; R 4和R 5可以相同或不同,各自表示烷基; R 6和R 7可以相同或不同,各自表示烷基或芳基; Q表示药学上可接受的阴离子; l表示1或2; m和n可以相同或不同,各自表示0或1; 和(B)药学上可接受的载体或稀释剂。 -
3.
公开(公告)号:US5169788A
公开(公告)日:1992-12-08
申请号:US363674
申请日:1989-06-09
CPC分类号: G01N33/5005 , G01N15/14 , G01N21/6428 , Y10S435/968 , Y10S436/80
摘要: Disclosed is a method of detecting a localized biochemical event in a cell, wherein said event results in a change in the membrane potential of that cell. The method includes treating the cell with a composition containing a lipophilic, cationic dye having a delocalized positive charge and the ability to undergo multiple changes in fluorescence spectra upon aggregation. The cell is treated with the dye for a time sufficient to enable the dye to associate with the cell. Dye which has not associated with the cell is then removed. Fluorescence is observed when the cell is exposed to light having a wavelength suitable for exciting the dye. The spectrum obtained is indicative of the relative membrane potential of said cell, and a change in that membrane potential being indicative of the occurrence of a biochemical event.
摘要翻译: 公开了一种检测细胞中局部生化事件的方法,其中所述事件导致该细胞的膜电位发生变化。 该方法包括用包含具有离域正电荷的亲脂阳离子染料和在聚集时经受多次荧光光谱变化的能力的组合物处理细胞。 用染料处理细胞足以使染料与细胞缔合的时间。 然后除去与细胞没有关联的染料。 当细胞暴露于适合于激发染料的波长的光时,观察到荧光。 获得的光谱指示所述细胞的相对膜电位,并且该膜电位的变化指示生化事件的发生。
-
公开(公告)号:US5196413A
公开(公告)日:1993-03-23
申请号:US660904
申请日:1991-02-27
CPC分类号: A61K31/28 , C07F15/0093 , C09B69/06
摘要: A (+)-charged dye transition metal complex, particularly a complex of platinum and a (+)-charged dye such as rhodamine 123. These products demonstrate antitumor and radio-sensitizing activity.
摘要翻译: (+)带电的染料过渡金属络合物,特别是铂和(+) - 带电染料如罗丹明123的络合物。这些产品表现出抗肿瘤和放射增敏活性。
-
公开(公告)号:US4921973A
公开(公告)日:1990-05-01
申请号:US186177
申请日:1988-04-26
CPC分类号: A61K31/28 , C07F15/0093 , C09B69/06
摘要: A (+)-charged dye transition metal complex, particularly a complex of platinum and a (+)-charged dye such as rhodamine 123. These products demonstrate antitumor and radio-sensitizing activity.
摘要翻译: (+)带电的染料过渡金属络合物,特别是铂和(+) - 带电染料如罗丹明123的络合物。这些产品表现出抗肿瘤和放射增敏活性。
-
-
-
-